Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity

Cancer Cell

Volumn 5, Issue 1, 2004, Pages 25-35

  Schimmer, Aaron D ^a   Welsh, Kate ^a   Pinilla, Clemencia ^b   Wang, Zhiliang ^a   Krajewska, Maryla ^a   Bonneau, Marie Josee ^a   Pedersen, Irene M ^a   Kitada, Shinichi ^a   Scott, Fiona L ^a   Bailly Maitre, Beatrice ^a   Glinsky, Gennadi ^c   Scudiero, Dominick ^d   Sausville, Edward ^d   Salvesen, Guy ^a   Nefzi, Adel ^b   Ostresh, John M ^b   Houghten, Richard A ^b   Reed, John C ^a  

^a BURNHAM INSTITUTE   (United States)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^c SIDNEY KIMMEL CANCER CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; CASPASE 3; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; PROTEIN INHIBITOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; X LINKED INHIBITOR OF APOPTOSIS ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; COLON CANCER; COMBINATORIAL LIBRARY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALIA; INTRACISTERNAL A-PARTICLES;

EID: 9144234685     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00332-5     Document Type: Article

References (45)

1. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48:1988;589-601.
2. Ashkenazi A., Dixit V.M. Death receptors. signaling and modulation Science. 281:1998;1305-1308.
3. Bilim V., Kasahara T., Hara N., Takahashi K., Tomita Y. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistance TCC in vitro. Int. J. Cancer. 103:2003;29-37.
4. Byrd J.C., Kitada S., Flinn I., Aron J.L., Pearson M., Lucas D., Reed J.C. The mechanism of tumor cell clearance by Rituximab in vivo in patients with B-cell chronic lymphocytic leukemia. evidence of caspase activation and apoptosis induction Blood. 99:2002;1038-1043.
5. Cryns V., Yuan Y. Proteases to die for. Genes Dev. 12:1999;1551-1570.
6. Deveraux Q.L., Takahashi R., Salvesen G.S., Reed J.C. X-linked IAP is a direct inhibitor of cell death proteases. Nature. 388:1997;300-304.
7. Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula M., Alnemri E.S., Salvesen G.S., Reed J.C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 17:1998;2215-2223.
8. Deveraux Q.L., Leo E., Stennicke H.R., Welsh K., Salvesen G.S., Reed J.C. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. 18:1999;5242-5251.
9. Dimitroulakos J., Ye L.Y., Benzaquen M., Moore M.J., Kamel-Reid S., Freedman M.H., Yeger H., Penn L.Z. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis. therapeutic implications Clin. Cancer Res. 7:2001;158-167.
10. Evan G.I., Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature. 411:2001;342-348.
11. Ferreira C.G., van der Valk P., Span S.W., Jonker J.M., Postmus P.E., Kruyt F.A., Giaccone G. Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann. Oncol. 12:2001;799-805.
12. Fulda S., Wick W., Weller M., Debatin K.M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 8:2002;808-815.
13. Gordon G.J., Appasani K., Parcells J.P., Mukhopadhyay N.K., Jaklitsch M.T., Richards W.G., Sugarbaker D.J., Bueno R. Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma. Carcinogenesis. 23:2002;1017-1024.
14. Harlin H., Reffey S.B., Duckett C.S., Lindsten T., Thompson C.B. Characterization of XIAP-deficient mice. Mol. Cell. Biol. 21:2001;3604-3608.
15. Hofmann H.S., Simm A., Hammer A., Silber R.E., Bartling B. Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer. J. Cancer Res. Clin. Oncol. 128:2002;554-560.
16. Holcik M., Thompson C.S., Yaraghi Z., Lefebvre C.A., MacKenzie A.E., Korneluk R.G. The hippocampal neurons of neuronal apoptosis inhibitory protein 1 (NAIP1)-deleted mice display increased vulnerability to kainic acid-induced injury. Proc. Natl. Acad. Sci. USA. 97:2000;2286-2290.
17. Krajewska M., Krajewski S., Turner B., Bubendorf L., Kallioniemi O.-P., Shabaik A., Vitiello A., Goddison S., Reed J.C. Elevated expression of inhibitor of apoptosis proteins (IAPs) in prostate cancer. Clin. Cancer Res. 9:2003;4914-4925.
18. Liston P., Fong W.G., Kelly N.L., Toji S., Miyazaki T., Conte D., Tamai K., Craig C.G., McBurney M.W., Korneluk R.G. Indentificaiton of XAF1 as an antagonist of XIAP anti-caspase activity. Nat. Cell Biol. 3:2001;128-133.
19. Liu Z., Sun C., Olejniczak E.T., Meadows R.P., Betz S.F., Oost T., Herrmann J., Wu J.C., Fesik S.W. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature. 408:2000;1004-1008.
20. Marusawa H., Matsuzawa S.-I., Welsh K., Zou H., Armstrong R., Tamm I., Reed J.C. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 22:2003;2729-2740.
21. Nefzi A., Ong N., Houghten R.A. An efficient two-step synthesis of mono-, di- and triureas from resin-bound amides. Tetrahedron Lett. 41:2000;5441-5446.
22. Ostresh J.M., Husar G.M., Blondelle S.E., Dörner B., Weber P.A., Houghten R.A. Libraries from libraries. Chemical transformation of combinatorial libraries to extend the range and repertoire of chemical diversity Proc. Natl. Acad. Sci. USA. 91:1994;11138-11142.
23. Pinilla C., Appel J.R., Blanc P., Houghten R.A. Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries. Biotechniques. 13:1992;901-905.
24. Pinilla C., Appel J.R., Borras E., Houghten R.A. Advances in the use of synthetic combinatorial chemistry. mixture-based libraries Nat. Med. 9:2003;118-122.
25. Reed J.C. The survivin saga goes in vivo. J. Clin. Invest. 108:2001;965-969.
26. Riedl S.J., Renatus M., Schwarzenbacher R., Zhou Q., Sun C., Fesik S.W., Liddington R.C., Salvesen G.S. Structural basis for the inhibition of caspase-3 by XIAP. Cell. 104:2001;791-800.
27. Roy N., Deveraux Q.L., Takashashi R., Salvesen G.S., Reed J.C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 16:1997;6914-6925.
28. Sasaki H., Sheng Y., Kotsuji F., Tsang B.K. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 60:2000;5659-5666.
29. Schimmer A.D., Munk-Pedersen I., Kitada S., Demiralp E., Minden M.D., Pinto R., Mah K., Andreeff M., Kipps T., Reed J.C. Functional blocks in Caspase activation pathways are common in leukemia and predict patient-response to induction chemotherapy. Cancer Res. 63:2003;1242-1248.
30. Srinivasula S.M., Hegde R., Saleh A., Datta P., Shiozaki E., Chai J., Lee R.-A., Robbins P.D., Fernandes-Alnemri T., Shi Y., Alnermi E.S. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature. 410:2001;112-116.
31. Stennicke H.R., Salvesen G.S. Biochemical characteristics of caspase-3, -6, -7, and -8. J. Biol. Chem. 272:1997;25719-25723.
32. Stennicke H.R., Deveraux Q.L., Humke E.W., Reed J.C., Dixit V.M., Salvesen G.S. Caspase-9 can be activated without proteolytic processing. J. Biol. Chem. 274:1999;8359-8362.
33. Stennicke H.R., Ryan C.A., Salvesen G.S. Reprieval from execution. the molecular basis of caspase inhibition Trends Biochem. Sci. 27:2002;94-101.
34. Sun C., Cal M., Gunasekera A., Meadows R., Wang H., Chen J., Zhang H., Wu W., Xu M., Ng S., Fesik S. NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP. Nature. 401:1999;818-821.
35. Suzuki Y., Imai Y., Nakayama H., Takahashi K., Takio K., Takahashi R. A serine protease HtrA2/Omi, is released from the mitochondria and interacts with XIAP, induces cell death. Mol. Cell. 8:2001;613-621.
36. Takahashi R., Deveraux Q.L., Tamm I., Welsh K., Assa-Munt N., Salvesen G.S., Reed J.C. A single BIR domain of XIAP sufficient for inhibiting caspases. J. Biol. Chem. 273:1998;7787-7790.
37. Tamm I., Kornblau S.M., Segall H., Krajewski S., Welsh K., Kitada S., Scudiero D.A., Tudor G., Qui Y.H., Monks A.et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res. 6:2000;1796-1803.
38. Thornberry N.A., Lazebnik Y. Caspases. enemies within Science. 281:1998;1312-1316.
39. Vucic D., Deshayes K., Ackerly H., Pisabarro M.T., Kadkhodayan S., Fairbrother W.J., Dixit V.M. SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). J. Biol. Chem. 277:2002;12275-12279.
40. Wu G., Chai J., Suber T.L., Wu J.-W., Du C., Wang X., Shi Y. Structural basis of IAP recognition by Smac/DIABLO. Nature. 408:2000;1008-1012.
41. Wu T.Y., Wagner K.W., Bursulaya B., Schultz P.G., Deveraux Q.L. Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction. Chem. Biol. 10:2003;759-767.
42. Xu G., Cirilli M., Huang Y., Rich R.L., Myszka D.G., Wu H. Covalent inhibition revaled by the crystal structure of the caspase-8/p35 complex. Nature. 410:2001;494-497.
43. Yang L., Cao Z., Yan H., Wood W.C. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells. implication for cancer specific therapy Cancer Res. 63:2003;6815-6824. a.
44. Yang L., Mashima T., Sato S., Mochizuki M., Sakamoto H., Yamori T., Oh-Hara T., Tsuruo T. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells. therapeutic effect of a novel polyarginine-conjugated Smac peptide Cancer Res. 63:2003;831-837. b.
45. Zhou Q., Snipas S., Orth K., Muzio M., Dixit V.M., Salvesen G.S. Target protease specificity of the viral serpin CrmA. analysis of five caspases J. Biol. Chem. 272:1997;7797-7800.